Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Cell Biol ; 15(9): 5196-202, 1995 Sep.
Article in English | MEDLINE | ID: mdl-7651437

ABSTRACT

Critical determinants of DNA recognition by p53 have been identified by a molecular genetic approach. The wild-type human p53 fragment containing amino acids 71 to 330 (p53(71-330)) was used for in vitro DNA binding assays, and full-length human p53 was used for transactivation assays with Saccharomyces cerevisiae. First, we defined the DNA binding specificity of the wild-type p53 fragment by using systematically altered forms of a known consensus DNA site. This refinement indicates that p53 binds with high affinity to two repeats of PuGPuCA.TGPyCPy, a further refinement of an earlier defined consensus half site PuPuPuC(A/T).(T/A) GPyPyPy. These results were further confirmed by transactivation assays of yeast by using full-length human p53 and systematically altered DNA sites. Dimers of the pentamer AGGCA oriented either head-to-head or tail-to-tail bound efficiently, but transactivation was facilitated only through head-to-head dimers. To determine the origins of specificity in DNA binding by p53, we identified mutations that lead to altered specificities of DNA binding. Single-amino-acid substitutions were made at several positions within the DNA binding domain of p53, and this set of p53 point mutants were tested with DNA site variants for DNA binding. DNA binding analyses showed that the mutants Lys-120 to Asn, Cys-277 to Gln or Arg, and Arg-283 to Gln bind to sites with noncanonical base pair changes at positions 2, 3, and 1 in the pentamer (PuGPuCA), respectively. Thus, we implicate these residues in amino acid-base pair contacts. Interestingly, mutant Cys-277 to Gln bound a consensus site as two and four monomers, as opposed to the wild-type p53 fragment, which invariably binds this site as four monomers.


Subject(s)
DNA/metabolism , Point Mutation , Tumor Suppressor Protein p53/metabolism , Base Sequence , Binding Sites/genetics , Consensus Sequence , Cross-Linking Reagents , DNA/genetics , Humans , Molecular Sequence Data , Peptide Fragments/metabolism , Protein Binding , Repetitive Sequences, Nucleic Acid , Saccharomyces cerevisiae/genetics , Transcriptional Activation , Tumor Suppressor Protein p53/genetics
2.
Gene ; 141(2): 293-7, 1994 Apr 20.
Article in English | MEDLINE | ID: mdl-8163205

ABSTRACT

Proteins of the tissue inhibitor of metalloproteinase (TIMP) family bind and inactivate matrix metalloproteinases such as collagenases and gelatinases. We report the cloning and sequencing of cDNAs encoding a novel human TIMP, which we designated TIMP-3, the third member of the human TIMP family. Degenerate PCR primers derived from highly conserved regions of TIMP family cDNAs amplified a 402-bp product from human fetal kidney cDNA. This product and a related 333-bp PCR product were used as probes to screen two cDNA libraries. Three TIMP-3 cDNA clones were isolated, including a 1240-bp fetal kidney clone that contained a complete TIMP-3 precursor coding region of 211 amino acids (aa). The deduced precursor protein includes twelve Cys and 27 other aa that are invariant in the TIMP family. The predicted aa sequence is 89, 39 and 46% identical to those of ChIMP-3, human TIMP-1 and human TIMP-2, respectively. Northern blot analyses detected three TIMP-3 mRNA bands of 2.2, 2.5 and 4.4 kb in several human cell lines.


Subject(s)
Metalloendopeptidases/antagonists & inhibitors , Neoplasm Proteins/genetics , Amino Acid Sequence , Base Sequence , Blotting, Northern , Cell Line , Cloning, Molecular , DNA, Complementary , Humans , Molecular Sequence Data , Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinase-3
3.
Mol Cell Biol ; 14(3): 1909-19, 1994 Mar.
Article in English | MEDLINE | ID: mdl-7509448

ABSTRACT

We used molecular cloning and functional analyses to extend the family of Neu differentiation factors (NDFs) and to explore the biochemical activity of different NDF isoforms. Exhaustive cloning revealed the existence of six distinct fibroblastic pro-NDFs, whose basic transmembrane structure includes an immunoglobulin-like motif and an epidermal growth factor (EGF)-like domain. Structural variation is confined to three domains: the C-terminal portion of the EGF-like domain (isoforms alpha and beta), the adjacent juxtamembrane stretch (isoforms 1 to 4), and the variable-length cytoplasmic domain (isoforms a, b, and c). Only certain combinations of the variable domains exist, and they display partial tissue specificity in their expression: pro-NDF-alpha 2 is the predominant form in mesenchymal cells, whereas pro-NDF-beta 1 is the major neuronal isoform. Only the transmembrane isoforms were glycosylated and secreted as biologically active 44-kDa glycoproteins, implying that the transmembrane domain functions as an internal signal peptide. Extensive glycosylation precedes proteolytic cleavage of pro-NDF but has no effect on receptor binding. By contrast, the EGF-like domain fully retains receptor binding activity when expressed separately, but its beta-type C terminus displays higher affinity than alpha-type NDFs. Likewise, structural heterogeneity of the cytoplasmic tails may determine isoform-specific rate of pro-NDF processing. Taken together, these results suggest that different NDF isoforms are generated by alternative splicing and perform distinct tissue-specific functions.


Subject(s)
Glycoproteins/chemistry , Neuregulin-1/agonists , Amino Acid Sequence , Animals , Base Sequence , Cloning, Molecular , DNA Primers/chemistry , DNA, Complementary/genetics , ErbB Receptors/metabolism , Gene Expression , Genes , Glycoproteins/genetics , Glycoproteins/physiology , Humans , Molecular Sequence Data , Molecular Weight , Neuregulins , Phosphotyrosine , Proto-Oncogene Proteins/metabolism , RNA, Messenger/genetics , Rats , Receptor, ErbB-2 , Recombinant Proteins , Sequence Alignment , Sequence Homology, Amino Acid , Transfection , Tyrosine/analogs & derivatives , Tyrosine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...